Ritonavir-boosted nirmatrelvir
Revision as of 20:19, 18 January 2022 by Rossdonaldson1 (talk | contribs)
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names: Paxlovid
Adult Dosing
COVID
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Nirmatrelvir tablets and ritonavir tablets (Paxlovid from Pfizer)
- treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) that are high risk
- initiate within 5 days of symptom onset
- 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
- renally dosed eGFR 30-60 then 150 mg/100 mg dosing
- 89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.
- Many drug interactions
- E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin
- DHS daily supply of COVID oral therapies
- List of community pharmacies that might have COVID antivirals
- Printable list for patients File:COVID-19 Antiviral Providers.pdf